Targazyme said today that it will begin enrolling patients in a Phase II clinical study to evaluate TZ101-fucosylated bone marrow stem cells in cancer patients, after the FDA granted the San Diego-based company investigational new drug clearance.
The treatment is designed to use blood-forming stem cells from bone marrow to restore the body’s ability to make blood and immune cells in patients with leukemia, lymphoma and some types of anemia. Targazyme is studying the modification of stem cells from haplo-identical donors – someone who is a 50% match to the recipient. Targazyme’s product, TZ101, modifies stem cells to improve their ability to home, adhere and engrant into the bone marrow. The company hopes this will accelerate hematopoietic recovery, reduce infection and lessen a cancer patient’s time in the hospital after the haplo-identical transplant.
Get the full story at our sister site, Drug Delivery Business News.
The post Targazyme wins FDA clearance for Phase II bone marrow stem cell study appeared first on MassDevice.
from MassDevice http://ift.tt/2eIyaWe
Cap comentari:
Publica un comentari a l'entrada